Therapeutic Effect of Symbicort Turbuhaler Combined with Respiratory Training on Pulmonary Function and Blood Gas Analysis in Patients with Stable Chronic Obstructive Pulmonary Disease

2019 ◽  
Vol 08 (02) ◽  
pp. 36-40
Author(s):  
彩平 李
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Function ◽  
Pulmonary Disease ◽  
Therapeutic Effect ◽  
Blood Gas Analysis ◽  
Gas Analysis ◽  
Chronic Obstructive ◽  
Blood Gas ◽  
Obstructive Pulmonary Disease ◽  
Respiratory Training

scholarly journals Analysis of the characteristics of patients admitted to Internal Medicine wards for exacerbation of chronic obstructive pulmonary disease, and discharge phase optimization. The SDO-ARCA Project of the Scientific Society FADOI

2020 ◽  
Vol 14 (3) ◽  
pp. 156-161
Author(s):  
Marco Candela ◽  
Claudio Norbiato ◽  
Mauro Campanini ◽  
Antonio Luca Brucato ◽  
Salvatore Di Simone ◽  
...  
Keyword(s):  
Internal Medicine ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Blood Gas Analysis ◽  
Gas Analysis ◽  
Chronic Obstructive ◽  
Post Discharge ◽  
Obstructive Pulmonary Disease ◽  
Exacerbation Of Copd ◽  
A Prospective Study

The purpose of this study was to have a nationwide snapshot of the characteristics of patients hospitalized in Internal Medicine Units (IMUs) for exacerbation of chronic obstructive pulmonary disease (COPD), and to assess applicability and contents of a specific Hospital Discharge Form for the patient with exacerbation of COPD discharged from IMUs. This was a prospective study in 44 IMUs in Italy, enrolling patients hospitalized with a diagnosis of COPD exacerbation. Information concerning clinical characteristics of patients, and treatment for COPD at discharge was collected. Specific documents for monitoring of clinical conditions and adherence to therapies as well as a form including individual indications for clinical controls, instrumental tests, etc. were provided upon discharge. Four hundred and seventy-two patients were enrolled (68% male). According to GOLD classification 2015, patients with classes A to D were 12%, 27%, 31%, and 30%, respectively. Triple therapy was prescribed in 14% of GOLD A and 51% of GOLD D patients. Around 10% of patients for each GOLD class received no specific therapy. The vast majority of patients (85%) received instructions on the correct use of inhalers, and in most cases (85%), the quality of counseling was considered optimal/adequate. Indication for performing chest X-ray, spirometry, or blood gas analysis following discharge was addressed to 29%, 59% and 52.1% of patients, respectively. The follow-up sheet for COPD used in our study was shown as applicable. This highlighted the need for greater awareness and more standardized procedures within IMUs in the post-discharge phase.

scholarly journals Identifying the most effective tool to assess health status of patients with acute exacerbation of chronic obstructive pulmonary disease -a prospective study

2019 ◽  
Author(s):  
ping chen ◽  
Aiyuan Zhou ◽  
Zijing Zhou ◽  
Dingding Deng ◽  
Yiyang Zhao ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Health Status ◽  
Lung Function ◽  
Blood Gas Analysis ◽  
Gas Analysis ◽  
Chronic Obstructive ◽  
Blood Gas ◽  
Obstructive Pulmonary Disease ◽  
Reported Health ◽  
Self Reported Health Status

Abstract Background: There is currently no recognized discharge criteria for patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). In clinical work, pulmonologists determine whether a patient can be discharged considering the patient self-reported health status and some measurements which are related to the health status of AECOPD patients. Various measurements have been used to evaluate health status in patients with AECOPD, including lung function, fractional exhaled nitric oxide (FENO), blood gas analysis, COPD Assessment Test (CAT) and modified Medical Research Council test (mMRC). However, which one is most closely related to the patient self-reported health status remains unknown. Methods: Patients with AECOPD were assessed at two visits: on admission and on day 7. The above measurements were tested at each visit. At the second visit, the patients were asked to report the health status according to a five-point Likert scale ranging from 1 to 5, representing ‘much better’, ‘slightly better’, ‘no change’, ‘slightly worse’ and ‘much worse’. Based on patients self-reported outcome, we defined the responders as those patients who reported “much better,” or “slightly better”, non-responders were those who reported ‘no change,’ ‘slightly worse’ or ‘much worse’. Results: 55 patients were recruited into analysis. FENO and CAT could change sensitively based on different health status, except failing to differentiate the patients between those who reported ‘slightly better’ and ‘no changes’. The changes in predicted percentage of forced expiratory volume in 1 s (FEV1%) didn’t change significantly between ‘no change’ group and ‘slightly better or much better’ group, it could only identify the ‘slightly worse’ patients. Although mMRC and blood gas analysis (PaO2, PaCO2) changed significantly after treatment, they didn’t reflect sensitively the evolution of health status. Among these measurements, the changes in CAT was best correlated with the evolution of health status (Rho=0.81), followed by FENO and FEV1%, the rho was 0.59 and -0.42, respectively. Conclusion: It’s reasonable to monitor CAT and FENO during exacerbation stage, the use of lung function and mMRC to evaluate the evolution of patients’ reported health status of patients with AECOPD is limited. Registry number: ChiCTR-ROC-16009087 (http://www.chictr.org.cn/).

SLOWING THE DETERIORATION OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE OBSERVED DURING BRONCHODILATOR THERAPY BY ADDING INHALED CORTICOSTEROIDS: A 4-YEAR PROSPECTIVE STUDY

PEDIATRICS ◽  
1994 ◽  
Vol 94 (2) ◽  
pp. 269-270
Author(s):  
Peter Cvietusa ◽  
Joseph Spahn ◽  
William R. Otto
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Function ◽  
Pulmonary Disease ◽  
Bronchial Hyperreactivity ◽  
Rapid Decline ◽  
Chronic Obstructive ◽  
Exacerbation Rate ◽  
Obstructive Pulmonary Disease ◽  
Bronchodilator Therapy ◽  
Inhaled Steroids

Purpose of the Study. To determine if the deterioration in lung function, seen in adults with asthma or chronic obstructive pulmonary disease (COPD), could be reversed or slowed by the addition of inhaled beclomethasone. Many short-term studies have shown the benefits of inhaled steroids in asthma; in particular, their ability to improve pulmonary function, decrease bronchial hyperreactivity, and reduce symptoms. Few studies have evaluated the long-term effects of inhaled steroids on the clinical course of either asthma or COPD. Methods. This report is an extension of a 2-year study that followed 160 patients with asthma or COPD on bronchodilator therapy alone. From this group, 56 patients who displayed a rapid decline in pulmonary function (FEV1 ≥ 80 ml/year) and a high exacerbation rate (≥1/year) were selected to receive additional treatment with beclomethasone dipropionate 400 µg two times daily over 4 years. FEV1 and airways responsiveness to histamine were measured every 6 months and at 1 and 13 months upon completion of the study. Peak flows and symptom scores were recorded weekly, and compliance, inhaler technique, and adverse affects were monitored every 3 months. Findings. During the first 6 months of beclomethasone treatment, both groups showed a significant improvement in pre- and postbronchodilator FEV1 with the most significant change noted in the asthma group. Thereafter, the FEV1 began to decline again, as it had in the first 2 years of the study, but at a rate that was 33% slower. In addition to slowing the decline in FEV1, inhaled beclomethasone resulted in a substantial decrease in the degree of bronchial hyperreactivity, and peak flow rates improved.

Sign in / Sign up

Export Citation Format

Share Document